Aspen Sells U.S. Arixtra Rights To Mylan For As Much As $300 Million
This article was originally published in PharmAsia News
Executive Summary
South Africa's Aspen Pharmacare said it has signed a deal to sell U.S. rights to with Mylan's Ireland unit for its Arixtra (fondaparinux) for treating deep-vein thrombosis for as much as $300 million.